Mazdutide Phase 2 Obesity Trial Results Published in Lancet Journal

On August 21, 2026, a new publication on mazdutide appeared in The Lancet Diabetes & Endocrinology. The paper, titled "Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial," reports on a phase 2 study conducted across multiple sites in the United States. The trial used a randomised, placebo-controlled design to evaluate mazdutide in participants with obesity or overweight. Mazdutide remains an unapproved compound under research investigation and is not currently approved for clinical use. This publication represents the release of trial findings in a peer-reviewed journal, as indexed under PubMed ID 42628555. No specific efficacy or safety outcomes from the study are detailed here beyond the fact of publication. Readers interested in the trial results should consult the full journal article for complete data on the study design, participant outcomes, and safety findings. For general background on mazdutide, including its development status and mechanism, readers can refer to the compound overview.